UNSPSC 51373414: Brompheniramine/codeine/guaifenesin/menthol/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373414 Brompheniramine/codeine/guaifenesin/menthol/phenylephrine/phenylpropanolamine (Commodity) covers pharmaceutical products and OTC medications that state and local governments procure through both direct purchase and cooperative-purchasing frameworks. Recent solicitations show state and local health departments, county health systems, and multistate cooperative alliances buying these products for distribution to community health facilities, emergency response programs, and public health initiatives, often specifying exact National Drug Codes, packaging configurations, and delivery schedules to support operational continuity across multiple jurisdictions and end-use sites.

Issuing bodies include county health departments (Seminole County, Florida) and state multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration's MMCAP, which serves participating Oregon jurisdictions alongside Minnesota). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) recently issued an RFP posted January 20, 2026, with a response deadline of March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through three authorized wholesalers and multiple state and local facilities; vendors must certify compliance with cGMP and the Drug Supply Chain Security Act, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) posted June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford. Activity appears concentrated in Florida and Minnesota, with multistate cooperative purchasing spanning Oregon and other MMCAP member jurisdictions.